280 related articles for article (PubMed ID: 20127498)
1. Targeting the bone microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Metab; 2010 May; 28(3):244-50. PubMed ID: 20127498
[TBL] [Abstract][Full Text] [Related]
2. Tumor-host cell interactions in the bone disease of myeloma.
Fowler JA; Edwards CM; Croucher PI
Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms, current management and next generation therapy in myeloma bone disease.
Heusschen R; Muller J; Duray E; Withofs N; Bolomsky A; Baron F; Beguin Y; Menu E; Ludwig H; Caers J
Leuk Lymphoma; 2018 Jan; 59(1):14-28. PubMed ID: 28573897
[TBL] [Abstract][Full Text] [Related]
4. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
5. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
6. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
[TBL] [Abstract][Full Text] [Related]
7. Bone metabolism regulation: Implications for the treatment of bone diseases.
Yao D; Huang L; Ke J; Zhang M; Xiao Q; Zhu X
Biomed Pharmacother; 2020 Sep; 129():110494. PubMed ID: 32887023
[TBL] [Abstract][Full Text] [Related]
8. Myeloma and Bone Disease.
Panaroni C; Yee AJ; Raje NS
Curr Osteoporos Rep; 2017 Oct; 15(5):483-498. PubMed ID: 28861842
[TBL] [Abstract][Full Text] [Related]
9. The pathogenesis of the bone disease of multiple myeloma.
Edwards CM; Zhuang J; Mundy GR
Bone; 2008 Jun; 42(6):1007-13. PubMed ID: 18406675
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
Giuliani N; Rizzoli V; Roodman GD
Blood; 2006 Dec; 108(13):3992-6. PubMed ID: 16917004
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates in multiple myeloma.
Apperley JF; Croucher PI
Pathol Biol (Paris); 1999 Feb; 47(2):178-81. PubMed ID: 10192885
[TBL] [Abstract][Full Text] [Related]
13. Bone disease in multiple myeloma.
Hjertner Ø; Standal T; Børset M; Sundan A; Waage A
Med Oncol; 2006; 23(4):431-41. PubMed ID: 17303901
[TBL] [Abstract][Full Text] [Related]
14. The effects of bortezomib on bone disease in patients with multiple myeloma.
Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
[TBL] [Abstract][Full Text] [Related]
15. Tranexamic Acid Promotes Murine Bone Marrow-Derived Osteoblast Proliferation and Inhibits Osteoclast Formation In Vitro.
Baranowsky A; Appelt J; Tseneva K; Jiang S; Jahn D; Tsitsilonis S; Frosch KH; Keller J
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33466312
[TBL] [Abstract][Full Text] [Related]
16. New agents in the Treatment of Myeloma Bone Disease.
Ring ES; Lawson MA; Snowden JA; Jolley I; Chantry AD
Calcif Tissue Int; 2018 Feb; 102(2):196-209. PubMed ID: 29098361
[TBL] [Abstract][Full Text] [Related]
17. Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
19. New potential targets for treating myeloma bone disease.
Roodman GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
Corso A; Ferretti E; Lazzarino M
Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
